AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives. AstraZeneca’s primary focus is on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). AstraZeneca is also active in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. AstraZeneca’s 51’500 employees deliver an annual turnover of approximately 18.7 billion €.AstraZeneca’s R&D site at Mölndal provides an inspiring and vibrant environment for scientists and researchers based on creativity, collaboration and courageous leadership. Research in Mölndal covers all stages of the development of pharmaceutics. Organometallic chemistry and catalysis are broadly used throughout the process, from the early development phases all the way to production. An integrated theoretical approach is applied synergistically with experimental research to accelerate the discovery process.